BioSpace News Archive

Thermo Fisher Scientific Inc., the world leader in serving science, announced that its Board of Directors has authorized a quarterly cash dividend of $0.35 per common share payable on April 14, 2023, to stockholders of record as of March 15, 2023.

ICON plc, a world-leading healthcare intelligence and clinical research organization, reported its financial results for the fourth quarter and year ended December 31, 2022.

Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) (“Genomma Lab” or “the Company”), today announced its results for the fourth quarter and full year ended December 31, 2022.

Apellis Pharmaceuticals, Inc. announced the pricing of its underwritten public offering of 3,174,603 shares of its common stock at a public offering price of $63.00 per share.

Ipsen S.A. announced that Anemone Acquisition Corp., its wholly owned indirect subsidiary, has extended the expiration time for the previously announced tender offer to purchase all of the issued and outstanding shares of common stock of Albireo Pharma, Inc. at a price of $42.00 per share.

BioInvent made significant advances in 2022, further developing our exciting pipeline of novel and first-in-class immuno-modulatory antibodies for cancer therapy and substantially reinforcing the company’s financial position.

Spanish pharmaceutical company Ferrer and Swiss clinical stage biotechnology company Asceneuron announce the signing of a licensing agreement in which Ferrer obtains the exclusive worldwide rights to develop and commercialize ASN90 in progressive supranuclear palsy, an orphan, tau-related disease with a high unmet medical need.

MannKind Corporation (Nasdaq: MNKD) announced today that it will present an oral presentation describing meal challenge results at the 16th International Conference on Advanced Technologies & Treatment for Diabetes (ATTD) in Berlin February 22-25.

CLEARA Biotech B.V. (“Cleara” or the “Company”) today announced that immunotherapy and oncology expert Dr. Nicholas J. Sarlis has been appointed as the company’s Chief Medical Officer (CMO) and Head of Clinical Development.

Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full year ended December 31, 2022, consistent with its preliminary financial results announced on January 10, 2023 and January 25, 2023.